Secondary analysis of clinical trial data suggests that a functional polymorphism ( rs1799971 , Asn40Asp ) of the - opioid receptor gene ( OPRM1 ) is associated with the risk of relapse to heavy drinking following treatment with the opioid antagonist naltrexone .